Who is the assignee on this patent?

Lopez Marc, Olive Daniel, Inst Nat Sante Rech Med, and 2 more

What technology area does this patent fall under?

Primary CPC classification C07K14/78. Mapped technology areas include Chemistry & Metallurgy.

When was this patent published?

Publication date Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).

Antigen peptide and uses thereof

US9266922B2 · US · B2

Patent metadata
Field	Value
Publication number	US-9266922-B2
Application number	US-201214122937-A
Country	US
Kind code	B2
Filing date	May 31, 2012
Priority date	Jun 1, 2011
Publication date	Feb 23, 2016
Grant date	Feb 23, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.

First claim

Opening claim text (preview).

The invention claimed is: 1. A genetically modified T lymphocyte that recognizes specifically an antigen peptide in complex with human leukocyte antigen A2 (HLA-A2), wherein said antigen peptide comprises an amino acid motif having the amino acid sequence: VLVPPLPSL (SEQ ID NO: 2). 2. A composition for adoptive therapy comprising a T lymphocyte according to claim 1 .

Assignees

Inventors

Classifications

C07K14/78Primary
Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] · CPC title
C12N2510/00
Genetically modified cells · CPC title
C07K14/4748Primary
Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title
C07K7/06Primary
having 5 to 11 amino acids · CPC title
C12N2501/998
Proteins not provided for elsewhere · CPC title

Patent family

Related publications grouped by family.

View patent family 46197273

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9266922B2 cover?: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
Who is the assignee on this patent?: Lopez Marc, Olive Daniel, Inst Nat Sante Rech Med, and 2 more
What technology area does this patent fall under?: Primary CPC classification C07K14/78. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?: Publication date Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).